Apixaban beat standard treatment Lovenox in preventing blood clots without increasing the risk of bleeding during a late-stage trial in patients who underwent knee surgery. Apixaban is a product of Pfizer and Bristol-Myers Squibb, which plan to submit the drug for European approval this year.

Full Story:

Related Summaries